Journal article
POS1342 depletion of KLRG1+ T CELLS in a first-in-human clinical trial of ABC008 in Inclusion Body Myositis (IBM)
Annals of the Rheumatic Diseases, Vol.81(Suppl. 1), pp.1008.3-1009
2022
Abstract
Background Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy is highly differentiated effector CD8+ cytotoxic T (Tc) cells invading non-necrotic myofibers [1]. These Tc cells, known to be relatively resistant to apoptosis, express markers including killer cell lectin-like receptor G1 (KLRG1) [2]. ABC008, a first-in-class humanized, afucosylated monoclonal antibody (mAb) specific for KLRG1, selectively depletes these highly differentiated Tc cells while sparing other blood cell populations, e.g., naïve, central memory, and regulatory T cells and B cells. ABC008 has been designed to treat diseases mediated by these Tc cells, including IBM and T-cell large granular lymphocytic leukemia (T-LGLL). IBM and rheumatoid arthritis overlap clinically with T-LGLL and share similar expansions of large granular lymphocytes (LGLs), which also express KLRG1. We report here our preliminary data from our ongoing trial of ABC008 in IBM (NCT04659031)...
Details
- Title
- POS1342 depletion of KLRG1+ T CELLS in a first-in-human clinical trial of ABC008 in Inclusion Body Myositis (IBM)
- Authors/Creators
- N. Goel (Author/Creator)M. Needham (Author/Creator)D. Soler-Ferran (Author/Creator)M.M. Cotreau (Author/Creator)J. Escobar (Author/Creator)S. Greenberg (Author/Creator)
- Publication Details
- Annals of the Rheumatic Diseases, Vol.81(Suppl. 1), pp.1008.3-1009
- Publisher
- BMJ Publishing Group
- Identifiers
- 991005541432807891
- Copyright
- © 2022 BMJ Publishing Group Ltd & European Alliance of Associations for Rheumatism.
- Murdoch Affiliation
- Centre for Molecular Medicine and Innovative Therapeutics
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
93 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.106 Rheumatology
- 1.106.1684 Dermatomyositis
- Web Of Science research areas
- Rheumatology
- ESI research areas
- Clinical Medicine